nexletol

Generic: bempedoic acid

nexletol: developed by 1 company · 1 FDA decision. Updated within the last hour.

Development Pipeline (1)

CompanyPhase
Esperion Therapeutics, Inc. (ESPR)Approved

FDA Decisions

Approval1 INDICATIONS AND USAGE NEXLETOL is indicated: to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin). as an adjunct to diet and exercise, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy i(ESPR)

Frequently asked questions

Who is developing nexletol?

nexletol is being developed by Esperion Therapeutics, Inc..

What is nexletol's latest FDA decision?

The most recent tracked FDA decision for nexletol is Approval for 1 INDICATIONS AND USAGE NEXLETOL is indicated: to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary revascularization) in adults at increased risk for these events who are unable to take recommended statin therapy (including those not taking a statin). as an adjunct to diet and exercise, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy i, dated February 21, 2020.

Get deeper analysis on nexletol

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis